JP2012518012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012518012A5 JP2012518012A5 JP2011550316A JP2011550316A JP2012518012A5 JP 2012518012 A5 JP2012518012 A5 JP 2012518012A5 JP 2011550316 A JP2011550316 A JP 2011550316A JP 2011550316 A JP2011550316 A JP 2011550316A JP 2012518012 A5 JP2012518012 A5 JP 2012518012A5
- Authority
- JP
- Japan
- Prior art keywords
- nanoparticle
- lipid
- group
- nanoparticles
- dspe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 36
- 150000002632 lipids Chemical class 0.000 claims description 34
- 239000002105 nanoparticle Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 15
- 239000002184 metal Substances 0.000 claims description 14
- 239000002738 chelating agent Substances 0.000 claims description 11
- 229910021645 metal ion Inorganic materials 0.000 claims description 11
- 150000003904 phospholipids Chemical class 0.000 claims description 11
- 229920001281 polyalkylene Polymers 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 8
- -1 acyl-peptides Natural products 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 230000005298 paramagnetic effect Effects 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- 229920002505 N-(Carbonyl-Methoxypolyethylene Glycol 2000)-1,2-Distearoyl-Sn-Glycero-3-Phosphoethanolamine Polymers 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical class C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 229930186217 Glycolipid Natural products 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- 239000003613 bile acid Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 239000012830 cancer therapeutic Substances 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- HZHFFEYYPYZMNU-UHFFFAOYSA-K gadodiamide Chemical compound [Gd+3].CNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NC HZHFFEYYPYZMNU-UHFFFAOYSA-K 0.000 claims description 2
- 229960005063 gadodiamide Drugs 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 229940071238 n-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine Drugs 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 150000008103 phosphatidic acids Chemical group 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- SRLOHQKOADWDBV-NRONOFSHSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC SRLOHQKOADWDBV-NRONOFSHSA-M 0.000 claims description 2
- 150000003408 sphingolipids Chemical class 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- DDTBPAQBQHZRDW-UHFFFAOYSA-N cyclododecane Chemical compound C1CCCCCCCCCCC1 DDTBPAQBQHZRDW-UHFFFAOYSA-N 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- 235000004426 flaxseed Nutrition 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical group 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15245909P | 2009-02-13 | 2009-02-13 | |
| US61/152,459 | 2009-02-13 | ||
| US16298909P | 2009-03-24 | 2009-03-24 | |
| US61/162,989 | 2009-03-24 | ||
| PCT/US2010/024324 WO2010094043A2 (en) | 2009-02-13 | 2010-02-16 | Gadolinium expressed lipid nanoparticles for magnetic resonance imaging |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015229868A Division JP6072205B2 (ja) | 2009-02-13 | 2015-11-25 | 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012518012A JP2012518012A (ja) | 2012-08-09 |
| JP2012518012A5 true JP2012518012A5 (enExample) | 2013-04-04 |
| JP5847588B2 JP5847588B2 (ja) | 2016-01-27 |
Family
ID=42562321
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011550316A Active JP5847588B2 (ja) | 2009-02-13 | 2010-02-16 | 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 |
| JP2015229868A Active JP6072205B2 (ja) | 2009-02-13 | 2015-11-25 | 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015229868A Active JP6072205B2 (ja) | 2009-02-13 | 2015-11-25 | 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20120087857A1 (enExample) |
| EP (1) | EP2398503B1 (enExample) |
| JP (2) | JP5847588B2 (enExample) |
| CN (2) | CN106362171A (enExample) |
| WO (1) | WO2010094043A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150064115A1 (en) * | 2012-04-05 | 2015-03-05 | University Of Florida Research Foundation, Inc. | Neurophilic nanoparticles |
| US20170332910A1 (en) * | 2014-11-03 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Modified paramagnetic nanoparticles for targeted delivery of therapeutics and methods thereof |
| GB201509934D0 (en) | 2015-06-08 | 2015-07-22 | King S College London | Nanoparticles |
| US10799456B2 (en) * | 2015-06-15 | 2020-10-13 | University Of Washington | Multiple drug lipid nanoparticle composition and related methods for extended drug levels in blood and lymph tissue |
| CN107412790B (zh) * | 2017-09-08 | 2019-02-22 | 丽水市中心医院 | 一种核磁共振纳米材料的制备方法 |
| WO2019211843A1 (en) * | 2018-04-30 | 2019-11-07 | Bar-Ilan University | Polymeric core-shell particles |
| WO2020154623A1 (en) * | 2019-01-24 | 2020-07-30 | Alzeca Biosciences, LLC | Functionalized liposomes for imaging misfolded proteins |
| JP7395759B2 (ja) * | 2020-01-29 | 2023-12-11 | テキサス チルドレンズ ホスピタル | アミロイド沈着のｍｒｉのための標的造影剤 |
| CN113730614B (zh) * | 2021-09-09 | 2022-02-22 | 南京市第一医院 | 一种镥标记的纳米载体及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833948A (en) * | 1995-06-15 | 1998-11-10 | Bracco Research S.A. | Blood-pool imaging composition comprising micelles containing a lipophilic chelating agent and a non-ionic surfactant |
| EP1105162A1 (en) * | 1998-08-10 | 2001-06-13 | Bracco Research S.A. | Combination of a positive mri contrast agent with a negative mri contrast agent |
| US20030082103A1 (en) * | 2000-10-11 | 2003-05-01 | Targesome, Inc. | Targeted therapeutic lipid constructs having cell surface targets |
| US7025987B2 (en) * | 2001-05-30 | 2006-04-11 | The Scripps Research Institute | Delivery system for nucleic acids |
| AU2003303954A1 (en) * | 2002-10-25 | 2004-10-11 | Emory University | Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring |
| EP2338525A3 (en) * | 2003-07-09 | 2011-08-03 | California Pacific Medical Center | Remote detection of substance delivery to cells |
| EP1696965B1 (en) | 2003-12-22 | 2014-12-10 | Bracco Suisse SA | Assembly of gas-filled microvesicle with active component for contrast imaging |
| CN1969190A (zh) * | 2004-04-20 | 2007-05-23 | 爱默蕾大学 | 多峰性纳米结构，其制造方法以及其使用方法 |
| US20090238767A1 (en) * | 2004-12-17 | 2009-09-24 | Koninklijke Philips Electronics, N.V. | Targeting contrast agents or targeting therapeutic agents for molecular imaging and therapy |
| US8753673B2 (en) * | 2006-05-23 | 2014-06-17 | Taiwan Liposome Co. Ltd. | Liposome composition for delivery of a therapeutic agent to eyes |
| CA2680206C (en) * | 2007-03-05 | 2015-07-07 | Washington University | Nanoparticle delivery systems for membrane-integrating peptides |
| KR20080094473A (ko) * | 2007-04-20 | 2008-10-23 | 한국화학연구원 | 음이온성 지질나노입자 및 이의 제조방법 |
| WO2009110939A2 (en) * | 2007-12-10 | 2009-09-11 | Massachusetts Institute Of Technology | Drug delivery system for pharmaceuticals and radiation |
-
2010
- 2010-02-16 CN CN201610996986.1A patent/CN106362171A/zh active Pending
- 2010-02-16 EP EP10741884.0A patent/EP2398503B1/en active Active
- 2010-02-16 CN CN2010800105605A patent/CN102341126A/zh active Pending
- 2010-02-16 JP JP2011550316A patent/JP5847588B2/ja active Active
- 2010-02-16 WO PCT/US2010/024324 patent/WO2010094043A2/en not_active Ceased
-
2011
- 2011-08-11 US US13/208,100 patent/US20120087857A1/en not_active Abandoned
-
2015
- 2015-11-25 JP JP2015229868A patent/JP6072205B2/ja active Active
-
2016
- 2016-12-05 US US15/369,661 patent/US11207430B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Diagnostic imaging and therapeutic application of nanoparticles targeting the liver | |
| JP2012518012A5 (enExample) | ||
| Kuai et al. | High-density lipoproteins: nature’s multifunctional nanoparticles | |
| US10525152B2 (en) | Methods and compositions for targeted imaging | |
| JP6072205B2 (ja) | 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 | |
| JP2016094425A5 (enExample) | ||
| JP4332507B2 (ja) | 医薬組成物 | |
| ES2848209T3 (es) | Direccionamiento específico de célula mediante sistemas portadores nanoestructurados | |
| JP2014526442A (ja) | アポトーシス−ターゲティングナノ粒子 | |
| JPH09512265A (ja) | コントラスト剤 | |
| JPH10507172A (ja) | リポソーム剤 | |
| PT1863448E (pt) | Novas composições de lipossomas | |
| CN103860468B (zh) | 一种t7肽修饰的zl006长循环脂质体及其制备方法 | |
| Iyer et al. | The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma | |
| JP2015502946A5 (enExample) | ||
| JP2024037760A (ja) | アミロイド沈着のｍｒｉのための標的造影剤 | |
| US6562371B1 (en) | Liposomes | |
| WO2021245547A1 (en) | Liposomal system with killer tnf-apoptosis induced ligand (killertrail), pro-apoptotic-directing | |
| US10894098B2 (en) | Methods and compositions for targeted imaging | |
| JP2006519262A (ja) | リポソームにより誘導される補体活性化の減少のためのリポソーム組成物 | |
| JP4827277B2 (ja) | リポソーム | |
| JP2019512484A (ja) | 骨髄、細網内皮系、および／またはリンパ節を標的にする放射標識リポソームならびにその診断用および治療用使用の方法 | |
| US20140363378A1 (en) | Self-assembling molecules that accumulate in acidic tumor microenvironments | |
| CN115260304A (zh) | 一种基于脂质的蛋白降解工具、应用及其制备方法 | |
| CA3192148A1 (en) | Galactosylated dendrimers for targeted intracellular delivery to hepatocytes |